MA50636A - Compositions et procédés pour inhiber l'activité d'arginase - Google Patents
Compositions et procédés pour inhiber l'activité d'arginaseInfo
- Publication number
- MA50636A MA50636A MA050636A MA50636A MA50636A MA 50636 A MA50636 A MA 50636A MA 050636 A MA050636 A MA 050636A MA 50636 A MA50636 A MA 50636A MA 50636 A MA50636 A MA 50636A
- Authority
- MA
- Morocco
- Prior art keywords
- arginase
- inhibiting
- compositions
- activity
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248632P | 2015-10-30 | 2015-10-30 | |
| US201662281964P | 2016-01-22 | 2016-01-22 | |
| US201662323034P | 2016-04-15 | 2016-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50636A true MA50636A (fr) | 2021-04-14 |
Family
ID=58631120
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050636A MA50636A (fr) | 2015-10-30 | 2016-10-28 | Compositions et procédés pour inhiber l'activité d'arginase |
| MA43131A MA43131B1 (fr) | 2015-10-30 | 2016-10-28 | Compositions et procédés d'inhibition de l'activité de l'arginase |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43131A MA43131B1 (fr) | 2015-10-30 | 2016-10-28 | Compositions et procédés d'inhibition de l'activité de l'arginase |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US10065974B2 (fr) |
| EP (3) | EP4011887A1 (fr) |
| JP (3) | JP6833844B2 (fr) |
| KR (2) | KR20220118559A (fr) |
| CN (4) | CN113150015A (fr) |
| AU (3) | AU2016343656B2 (fr) |
| BR (3) | BR122020022275B1 (fr) |
| CA (1) | CA3003271A1 (fr) |
| CL (4) | CL2018001134A1 (fr) |
| CO (1) | CO2018004750A2 (fr) |
| CR (3) | CR20210390A (fr) |
| CY (1) | CY1123557T1 (fr) |
| DK (1) | DK3368541T3 (fr) |
| EA (1) | EA038276B1 (fr) |
| EC (1) | ECSP18040250A (fr) |
| ES (2) | ES2910928T3 (fr) |
| HK (1) | HK1252560A1 (fr) |
| HR (1) | HRP20201046T1 (fr) |
| HU (1) | HUE054972T2 (fr) |
| IL (3) | IL258731B (fr) |
| LT (1) | LT3368541T (fr) |
| MA (2) | MA50636A (fr) |
| MD (1) | MD3368541T2 (fr) |
| MX (1) | MX2018005294A (fr) |
| NZ (1) | NZ742742A (fr) |
| PH (1) | PH12018500899A1 (fr) |
| PL (1) | PL3368541T3 (fr) |
| PT (1) | PT3368541T (fr) |
| RS (1) | RS60695B1 (fr) |
| SG (4) | SG10201911402YA (fr) |
| SI (1) | SI3368541T1 (fr) |
| TW (3) | TWI775556B (fr) |
| UA (1) | UA125289C2 (fr) |
| WO (1) | WO2017075363A1 (fr) |
| ZA (4) | ZA201803556B (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2586219C2 (ru) | 2010-04-22 | 2016-06-10 | Марс, Инкорпорейтед | Ингибиторы аргиназы и их терапевтические применения |
| ES2568680T3 (es) | 2010-10-26 | 2016-05-03 | Mars, Incorporated | Boratos como inhibidores de arginasa |
| KR20220118559A (ko) | 2015-10-30 | 2022-08-25 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 아르기닌 활성 억제용 조성물 및 방법 |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| WO2018089490A1 (fr) * | 2016-11-08 | 2018-05-17 | Calithera Biosciences, Inc. | Polythérapies faisant appel à un inhibiteur d'arginase |
| DK3559009T3 (da) * | 2016-12-22 | 2021-05-03 | Calithera Biosciences Inc | Sammensætninger og metoder til inhibition af arginaseaktivitet |
| US10494339B2 (en) | 2017-05-12 | 2019-12-03 | Calithera Biosciences, Inc. | Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide |
| WO2019120296A1 (fr) * | 2017-12-22 | 2019-06-27 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Composés hétérocycliques utilisés en tant qu'inhibiteurs de l'arginase |
| UY38096A (es) | 2018-02-17 | 2019-07-31 | Astrazeneca Ab | Inhibidores de arginasa y sus métodos de uso |
| EP3765006A4 (fr) * | 2018-03-13 | 2022-02-23 | Merck Sharp & Dohme Corp. | Inhibiteurs d'arginase et procédés d'utilisation |
| WO2019186497A1 (fr) | 2018-03-29 | 2019-10-03 | Oncoarendi Therapeutics S.A. | Dérivés de pipéridine dipeptidiques |
| US11274111B2 (en) | 2018-06-20 | 2022-03-15 | Merck Sharp & Dohme Corp. | Arginase inhibitors and methods of use |
| CN109364252B (zh) * | 2018-11-21 | 2021-09-28 | 南京大学 | 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用 |
| WO2020160707A1 (fr) * | 2019-02-06 | 2020-08-13 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Acides alkylboroniques en tant qu'inhibiteurs d'arginase |
| CN110615753A (zh) * | 2019-09-02 | 2019-12-27 | 南京新酶合医药科技有限公司 | 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法 |
| CN110759843A (zh) * | 2019-09-30 | 2020-02-07 | 东北师范大学 | 一种氟叠氮取代的四元杂环化合物的制备和应用 |
| CN110734456A (zh) * | 2019-11-06 | 2020-01-31 | 南京谷睿生物科技有限公司 | 一种化合物及其制备方法和医药上的应用 |
| WO2021141751A1 (fr) * | 2020-01-07 | 2021-07-15 | Merck Sharp & Dohme Corp. | Inhibiteurs d'arginase et méthodes d'utilisation |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| EP4175719A1 (fr) | 2020-07-02 | 2023-05-10 | Incyte Corporation | Composés d'urée tricycliques en tant qu'inhibiteurs de v617f de jak2 |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US20220041630A1 (en) | 2020-07-17 | 2022-02-10 | Incyte Corporation | Processes for the preparation of arginase inhibitors and their synthetic intermediates |
| WO2022046989A1 (fr) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Composés d'urée tricycliques en tant qu'inhibiteurs de v617f de jak2 |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| EP4298099A1 (fr) | 2021-02-25 | 2024-01-03 | Incyte Corporation | Lactames spirocycliques utilisés comme inhibiteurs du v617f de jak2 |
| WO2023178285A1 (fr) | 2022-03-17 | 2023-09-21 | Incyte Corporation | Composés d'urée tricycliques en tant qu'inhibiteurs de jak2 v617f |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| CN1229110C (zh) | 1997-07-29 | 2005-11-30 | 阿尔康实验室公司 | 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物 |
| CA2305703A1 (fr) | 1997-10-10 | 1999-04-22 | David W. Christianson | Compositions et procedes pour inhiber l'activite de l'arginase |
| EP1051167A1 (fr) | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Utilisations pharmaceutiques de (-)-bupropion optiquement pur |
| US20040063666A1 (en) | 1998-10-09 | 2004-04-01 | David Christianson | Compositions for inhibiting arginase activity |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| EP1299398A1 (fr) | 2000-07-06 | 2003-04-09 | Fal Diagnostics | Procedes et trousses de detection de composes d'arginine |
| CA2431080A1 (fr) | 2003-06-02 | 2004-12-02 | Catherine Adele O'brien | Amelioration de l'immunite contre le cancer par l'intermediaire de l'inhibition de l'arginase |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| DK1654002T4 (da) | 2003-08-07 | 2014-02-17 | Allergan Inc | Sammensætninger til fremføring af terapeutiske midler til øjnene |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| EP1915143A4 (fr) | 2005-07-01 | 2009-11-11 | Univ Johns Hopkins | Arginase ii: traitement ciblé du vieillissement cardiaque et de l'insuffisance cardiaque |
| JP5386353B2 (ja) | 2007-07-12 | 2014-01-15 | 山洋電気株式会社 | 二重反転式軸流送風機 |
| EP2214660A2 (fr) * | 2007-10-12 | 2010-08-11 | Resolvyx Pharmaceuticals, Inc. | Acides gras de type oméga-3, acides gras polyinsaturés hydroxylés, composés de lipoxine ou composés d'oxylipine pour le traitement de maladies ophtalmiques |
| MX2010012064A (es) * | 2008-05-05 | 2010-12-06 | Schering Corp | Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer. |
| DK2389352T3 (da) * | 2009-01-26 | 2019-07-29 | Univ Pennsylvania | Arginaseinhibitorer og anvendelsesfremgangsmåder |
| RU2586219C2 (ru) | 2010-04-22 | 2016-06-10 | Марс, Инкорпорейтед | Ингибиторы аргиназы и их терапевтические применения |
| ES2568680T3 (es) * | 2010-10-26 | 2016-05-03 | Mars, Incorporated | Boratos como inhibidores de arginasa |
| EP2658580A4 (fr) * | 2010-12-31 | 2014-07-23 | Corridor Pharmaceuticals Inc | Inhibiteurs de l'arginase et leurs procédés d'utilisation |
| AU2012326109A1 (en) | 2011-10-19 | 2014-05-29 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| AU2012325909B2 (en) | 2011-10-20 | 2016-06-09 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| EP2852598B3 (fr) | 2012-04-18 | 2016-10-19 | Mars, Incorporated | Analogues à cycle contraint en tant qu'inhibiteurs d'arginase |
| BR112015010059A2 (pt) * | 2012-11-02 | 2017-07-11 | Pharmacyclics Inc | terapia adjuvante com inibidor da quinase da família tec |
| CN105848680A (zh) | 2013-10-25 | 2016-08-10 | 药品循环有限责任公司 | 使用布鲁顿酪氨酸激酶抑制剂和免疫疗法的治疗 |
| CN105879030A (zh) * | 2014-09-30 | 2016-08-24 | 复旦大学 | 治疗肿瘤的增效药物复合物及其制备方法 |
| KR20170129896A (ko) | 2015-03-20 | 2017-11-27 | 새미 오유 오피요 | 악성 신생물에 대한 수라민 및 아르기나아제 억제제의 용도 |
| JP2018520352A (ja) | 2015-06-23 | 2018-07-26 | カリセラ バイオサイエンシズ，インコーポレイテッド | アルギナーゼ活性を阻害するための組成物および方法 |
| KR20220118559A (ko) | 2015-10-30 | 2022-08-25 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 아르기닌 활성 억제용 조성물 및 방법 |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
-
2016
- 2016-10-28 KR KR1020227028040A patent/KR20220118559A/ko active Search and Examination
- 2016-10-28 BR BR122020022275-1A patent/BR122020022275B1/pt active IP Right Grant
- 2016-10-28 JP JP2018522126A patent/JP6833844B2/ja active Active
- 2016-10-28 TW TW110129153A patent/TWI775556B/zh active
- 2016-10-28 WO PCT/US2016/059342 patent/WO2017075363A1/fr active Application Filing
- 2016-10-28 TW TW105135189A patent/TWI710565B/zh active
- 2016-10-28 DK DK16860883.4T patent/DK3368541T3/da active
- 2016-10-28 EP EP22150809.6A patent/EP4011887A1/fr active Pending
- 2016-10-28 TW TW109135297A patent/TWI734630B/zh active
- 2016-10-28 CN CN202110097870.5A patent/CN113150015A/zh active Pending
- 2016-10-28 SG SG10201911402YA patent/SG10201911402YA/en unknown
- 2016-10-28 MA MA050636A patent/MA50636A/fr unknown
- 2016-10-28 PT PT168608834T patent/PT3368541T/pt unknown
- 2016-10-28 RS RS20200836A patent/RS60695B1/sr unknown
- 2016-10-28 MA MA43131A patent/MA43131B1/fr unknown
- 2016-10-28 CA CA3003271A patent/CA3003271A1/fr active Pending
- 2016-10-28 SI SI201630892T patent/SI3368541T1/sl unknown
- 2016-10-28 BR BR112018008746-7A patent/BR112018008746B1/pt active IP Right Grant
- 2016-10-28 SG SG10201911406TA patent/SG10201911406TA/en unknown
- 2016-10-28 CR CR20210390A patent/CR20210390A/es unknown
- 2016-10-28 PL PL16860883T patent/PL3368541T3/pl unknown
- 2016-10-28 MX MX2018005294A patent/MX2018005294A/es unknown
- 2016-10-28 SG SG11201802961PA patent/SG11201802961PA/en unknown
- 2016-10-28 EP EP16860883.4A patent/EP3368541B1/fr active Active
- 2016-10-28 NZ NZ742742A patent/NZ742742A/en unknown
- 2016-10-28 CN CN202110099500.5A patent/CN113201002A/zh active Pending
- 2016-10-28 MD MDE20180870T patent/MD3368541T2/ro unknown
- 2016-10-28 BR BR122020022280-8A patent/BR122020022280B1/pt active IP Right Grant
- 2016-10-28 CR CR20180282A patent/CR20180282A/es unknown
- 2016-10-28 CN CN202110099502.4A patent/CN113150016A/zh active Pending
- 2016-10-28 US US15/337,041 patent/US10065974B2/en active Active
- 2016-10-28 ES ES20165627T patent/ES2910928T3/es active Active
- 2016-10-28 UA UAA201805902A patent/UA125289C2/uk unknown
- 2016-10-28 KR KR1020187015208A patent/KR102434308B1/ko active IP Right Grant
- 2016-10-28 ES ES16860883T patent/ES2808988T3/es active Active
- 2016-10-28 CN CN201680063897.XA patent/CN108271371B/zh active Active
- 2016-10-28 CR CR20210389A patent/CR20210389A/es unknown
- 2016-10-28 AU AU2016343656A patent/AU2016343656B2/en active Active
- 2016-10-28 HU HUE16860883A patent/HUE054972T2/hu unknown
- 2016-10-28 EA EA201891057A patent/EA038276B1/ru unknown
- 2016-10-28 LT LTEP16860883.4T patent/LT3368541T/lt unknown
- 2016-10-28 EP EP20165627.9A patent/EP3693375B1/fr active Active
- 2016-10-28 SG SG10202003966RA patent/SG10202003966RA/en unknown
-
2018
- 2018-04-16 IL IL258731A patent/IL258731B/en active IP Right Grant
- 2018-04-26 PH PH12018500899A patent/PH12018500899A1/en unknown
- 2018-04-27 CL CL2018001134A patent/CL2018001134A1/es unknown
- 2018-05-02 CO CONC2018/0004750A patent/CO2018004750A2/es unknown
- 2018-05-28 EC ECIEPI201840250A patent/ECSP18040250A/es unknown
- 2018-05-29 ZA ZA2018/03556A patent/ZA201803556B/en unknown
- 2018-08-10 US US16/101,275 patent/US10851118B2/en active Active
- 2018-09-14 HK HK18111873.9A patent/HK1252560A1/zh unknown
-
2019
- 2019-03-28 CL CL2019000821A patent/CL2019000821A1/es unknown
- 2019-03-28 CL CL2019000820A patent/CL2019000820A1/es unknown
- 2019-03-28 CL CL2019000819A patent/CL2019000819A1/es unknown
- 2019-10-28 ZA ZA2019/07092A patent/ZA201907092B/en unknown
- 2019-10-28 ZA ZA2019/07091A patent/ZA201907091B/en unknown
- 2019-10-28 ZA ZA2019/07093A patent/ZA201907093B/en unknown
-
2020
- 2020-03-23 US US16/827,503 patent/US10844080B2/en active Active
- 2020-07-02 HR HRP20201046TT patent/HRP20201046T1/hr unknown
- 2020-08-21 CY CY20201100780T patent/CY1123557T1/el unknown
- 2020-11-12 US US17/096,500 patent/US20210061822A1/en not_active Abandoned
- 2020-12-10 AU AU2020286278A patent/AU2020286278B2/en active Active
-
2021
- 2021-02-02 JP JP2021014795A patent/JP7032583B2/ja active Active
- 2021-03-15 IL IL281503A patent/IL281503B/en unknown
- 2021-11-18 IL IL288225A patent/IL288225A/en unknown
-
2022
- 2022-02-22 JP JP2022025334A patent/JP2022071010A/ja not_active Withdrawn
- 2022-05-31 AU AU2022203703A patent/AU2022203703A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50636A (fr) | Compositions et procédés pour inhiber l'activité d'arginase | |
| MA42269A (fr) | Compositions et procédés d'inhibition de l'activité de l'arginase | |
| IL267532B (en) | Preparations and methods for inhibiting arginase activity | |
| MA46427A (fr) | Compositions d'oligonucléotides et procédés associés | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| MA41253A (fr) | Composés, compositions et procédés pour augmenter l'activité du cftr | |
| MA44990A (fr) | Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1 | |
| MA45688A (fr) | Compositions et procédés de potentialisation d'agents antimicrobiens | |
| MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
| MA43365A (fr) | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci | |
| MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
| MA45270A (fr) | Compositions d'oligonucléotides et procédés associés | |
| MA42488A (fr) | Composés, compositions et procédés pour augmenter l'activité du cftr | |
| MA40512A (fr) | Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants | |
| MA41198A (fr) | Essais d'activité enzymatique pour i2s | |
| MA42497A (fr) | Procédés et compositions pour la régulation sélective de l'expression protéique | |
| MA40904A (fr) | Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie | |
| MA45326A (fr) | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation | |
| MA51151A (fr) | Inhibiteurs d'endo-exonucléase mono- et di-amidine et procédés d'inhibition de l'activité endo-exonucléase | |
| MA43426A (fr) | Compositions et procédés permettant d'administrer des agents thérapeutiques |